David W. Nassif
CFO, Chief Legal Officer & Corporate SecretaryMr. David W. Nassif, J.D., serves as Chief Executive Officer of Sio Gene Therapies Inc. since May 2022 and also serves as its General Counsel since July 01, 2019 and serves as its Chief Financial Officer. He is the Chief Financial Officer of Pharvaris N.V. since April 15, 2024 and serves as its Corporate Secretary since June 01, 2024 and serves as its Chief Legal Officer since August 01, 2024. He serves as Chief Accounting Officer at Sio Gene Therapies Inc. since November 2020 and serves as its Director since January 2022 and served as its Interim Chief Executive Officer since January 2022 until May 2022. He served as Principal Accounting Officer of Sio Gene Therapies, Inc. since July 1, 2019. Mr. Nassif served as Chief Financial Officer and Executive Vice President of SteadyMed Therapeutics, a specialty pharmaceutical company, from March 2013 (first as a financial consultant and commencing March 2015 on a full-time basis) until June 2019, where he was instrumental in its acquisition by United Therapeutics in August 2018. He served as the Principal Financial and Accounting Officer, General Counsel of Axovant Gene Therapies Limitedfrom July 2019 until November 2020 and as the Chief Financial Officer of Axovant Sciences, Incorporatedfrom July 2019 through December 2020. Mr. Nassif had been the Chief Financial Officer and Executive Vice President of SteadyMed Ltd. since March 2013. Prior to joining SteadyMed Ltd., Mr. Nassif served as the President and Chief Financial Officer of Histogen, Inc. since May 2011 until September 2014. He served as Chief Financial Officer, Treasurer, Secretary and an Executive Vice President of Zogenix, Inc. from May 2007 to February 2010 and served as its Principal Accounting Officer. He has extensive industry experience in executive financial management roles in both development-stage and commercial-stage companies with both public and private companies. He served as a Consultant of Amphastar Pharmaceuticals Inc. He served as Chief Financial Officer and Senior Vice President of Amphastar Pharmaceuticals Inc. from May 2002 to 2006 and served as its Principal Accounting Officer, Treasurer for Global Licensing since July 2002. He was responsible for the acquisition of a marketed product and an inhalation therapy company. He served as Vice President of Global Licensing for Amphastar Pharmaceuticals Inc. from May 2002 to July 2002 and Senior Vice President of Global Licensing since July 2002. From March 2001 to May 2002, he served as Principal in Strategic Consulting Services, providing capital raising, mergers and acquisitions, licensing and Investor Relations services to various public and private life science and technology companies, including Amphastar. From January 2000 to March 2001, he served as the Senior Vice President, Chief Financial Officer, Treasurer and Secretary of RealAge Inc. From August 1993 to December 1999, Mr. Nassif held various positions with Questcor Pharmaceuticals, Inc. (a/k/a, Cypros Pharmaceutical Corporation). He served as Senior Vice President, Chief Financial Officer, Treasurer and Secretary at Questcor Pharmaceuticals, Inc. He holds a BS in Finance and Management Information Systems from the University of Virginia and a JD from the University Of Virginia School Of Law.
Positions
- Company NamePharvaris N.V.Stock CodePHVSPositionCFO, Chief Legal Officer & Corporate SecretaryColleagues
- BABerndt Axel Edvard ModigCo-Founder, CEO & Executive Director
- DPDavid P. MeekerIndependent Non-Executive Chair
- PLPeng LuPresident
- ANAnna NijdamHead of Strategic Finance & Principal Accounting Officer
- SAStefan AbeleChief Technology Operations Officer
- HJHans J. G. C. P. SchikanIndependent & Non-Executive Vice Chairman
- VMViviane MongesIndependent Non-Executive Director
- RGRobert GlassmanIndependent Non-Executive Director
